NasdaqGS:INBXBiotechs
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?
Inhibrx Biosciences (INBX) stock is reacting to a major regulatory milestone after the FDA accepted the Biologics License Application for ozekibart in unresectable or metastatic conventional chondrosarcoma, supported by positive ChonDRAgon phase III data.
See our latest analysis for Inhibrx Biosciences.
At a share price of $94.81, Inhibrx Biosciences has seen strong momentum over the past quarter, with a 90 day share price return of 62.37%, while the 1 year total shareholder return is very...